天新药业
(603235)
| 流通市值：40.81亿 | | | 总市值：121.48亿 |
| 流通股本：1.47亿 | | | 总股本：4.38亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,630,945,301.49 | 1,122,350,298.53 | 618,910,665.47 | 2,208,570,173.44 |
| 营业收入 | 1,630,945,301.49 | 1,122,350,298.53 | 618,910,665.47 | 2,208,570,173.44 |
| 二、营业总成本 | 1,105,745,608.76 | 710,909,338.89 | 371,946,946.36 | 1,474,222,808.06 |
| 营业成本 | 891,446,362.73 | 585,514,347.36 | 310,504,139.19 | 1,280,721,611.98 |
| 税金及附加 | 20,482,624.99 | 11,416,757.77 | 4,853,558.64 | 22,726,602.49 |
| 销售费用 | 26,950,112.5 | 19,847,242.95 | 8,694,796.65 | 32,849,944.34 |
| 管理费用 | 123,484,398.3 | 77,512,431.8 | 35,356,960.95 | 144,174,525.13 |
| 研发费用 | 71,324,408.74 | 42,459,796.68 | 20,722,319.47 | 103,818,345.37 |
| 财务费用 | -27,942,298.5 | -25,841,237.67 | -8,184,828.54 | -110,068,221.25 |
| 其中:利息费用 | 5,465,461.32 | 3,973,907.09 | - | 3,950,394.8 |
| 其中:利息收入 | 27,283,093.21 | 17,480,303.67 | 14,257,098.01 | 59,361,872.31 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 465,538.02 | 465,538.02 | -2,208,868.2 | 2,238,666.8 |
| 加:投资收益 | 6,155,700.75 | 4,121,010.46 | 3,822,583.42 | 5,444,358.6 |
| 资产处置收益 | -10,296.4 | -10,296.5 | -407.12 | 962.33 |
| 资产减值损失(新) | -14,003,597.41 | -14,004,087.93 | - | -7,542,795.49 |
| 信用减值损失(新) | 2,922,880.98 | 1,044,634.2 | -780,792.6 | -3,463,779.99 |
| 其他收益 | 32,531,977.98 | 22,171,901.58 | 12,108,734.03 | 43,330,750.67 |
| 四、营业利润 | 553,261,896.65 | 425,229,659.47 | 259,904,968.64 | 774,355,528.3 |
| 加:营业外收入 | 969,826.46 | 438,110.31 | 81,612.14 | 1,060,805.27 |
| 减:营业外支出 | 2,586,643.3 | 1,078,229.52 | 70,860.72 | 3,643,954.34 |
| 五、利润总额 | 551,645,079.81 | 424,589,540.26 | 259,915,720.06 | 771,772,379.23 |
| 减:所得税费用 | 91,341,203.68 | 68,575,990.96 | 41,348,618.32 | 120,549,239.62 |
| 六、净利润 | 460,303,876.13 | 356,013,549.3 | 218,567,101.74 | 651,223,139.61 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 460,303,876.13 | 356,013,549.3 | 218,567,101.74 | 651,223,139.61 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 460,303,876.13 | 356,013,549.3 | 218,567,101.74 | 651,223,139.61 |
| 扣除非经常损益后的净利润 | 430,953,785.84 | 336,278,264.05 | 208,976,403.83 | 614,419,922.59 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.06 | 0.82 | 0.5 | 1.49 |
| (二)稀释每股收益 | 1.06 | 0.82 | 0.5 | 1.49 |
| 九、综合收益总额 | 460,303,876.13 | 356,013,549.3 | 218,567,101.74 | 651,223,139.61 |
| 归属于母公司股东的综合收益总额 | 460,303,876.13 | 356,013,549.3 | 218,567,101.74 | 651,223,139.61 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |